CONSORT diagram showing No. of patients enrolled (N = 5,052), No. of eligible patients included in efficacy analysis (n = 4,954), and clinical outcomes for patients with predefined breast cancer subtypes of triple-negative breast cancer (TN), hormone receptor–positive, human epidermal growth factor receptor 2 (HER2) –nonoverexpressing breast cancer (HR+), and HER2-overexpressing breast cancer (HER2+). DFS, disease-free survival.